Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in EUR (TTM)203.50m
- Net income in EUR-456.34m
- Incorporated1998
- Employees464.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formycon AG | 77.70m | 75.80m | 771.61m | 238.00 | 9.30 | 1.40 | 9.93 | 9.93 | 4.70 | 4.70 | 4.84 | 31.32 | 0.0891 | 104.80 | 3.56 | 326,453.80 | 8.69 | 5.87 | 9.33 | 6.33 | 30.00 | 28.54 | 97.55 | 39.76 | 0.9621 | -0.0189 | 0.0176 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
Eckert & Ziegler SE | 255.78m | 34.32m | 976.87m | 1.07k | 28.02 | 4.09 | 20.08 | 3.82 | 1.65 | 1.44 | 12.27 | 11.29 | 0.5834 | 3.08 | 4.72 | 237,931.20 | 7.98 | 8.50 | 9.75 | 10.23 | 48.42 | 48.61 | 13.68 | 14.00 | 2.24 | 21.89 | 0.1919 | 35.09 | 10.74 | 7.84 | -2.84 | 13.22 | 33.82 | -30.12 |
Biotest AG | 782.60m | 176.90m | 1.38bn | 2.43k | 9.31 | 3.12 | -- | 1.76 | 4.47 | 4.47 | 19.78 | 13.34 | 0.5936 | 1.14 | 3.83 | 322,588.60 | 13.42 | -0.0693 | 16.72 | -0.079 | 44.24 | 28.43 | 22.60 | -0.1527 | 0.9139 | 5.34 | 0.5677 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
Evotec SE | 776.60m | -90.69m | 1.71bn | 5.06k | -- | 1.54 | -- | 2.20 | -0.5124 | -0.5124 | 4.39 | 6.24 | -- | -- | -- | 153,447.10 | -- | -0.0064 | -- | -0.0076 | 20.16 | 24.51 | -11.68 | -0.0178 | 1.79 | -2.09 | 0.3619 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
Dermapharm Holding SE | 1.11bn | 56.58m | 2.00bn | 3.50k | 35.33 | 3.43 | 12.19 | 1.79 | 1.05 | 1.05 | 20.69 | 10.81 | 0.5137 | 1.25 | 9.68 | 318,823.00 | 2.51 | 8.68 | 3.01 | 10.06 | 63.32 | 61.94 | 4.89 | 12.31 | 0.7517 | 2.70 | 0.6367 | 54.69 | 10.79 | 14.68 | -53.54 | -3.70 | 9.85 | -- |
MorphoSys AG | 203.50m | -456.34m | 2.57bn | 464.00 | -- | -- | -- | 12.64 | -12.54 | -12.65 | 5.79 | -6.95 | 0.1002 | 1.86 | 4.58 | 388,358.00 | -22.47 | -10.25 | -27.58 | -11.61 | 83.89 | 85.92 | -224.25 | -78.53 | 1.38 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
Qiagen NV | 1.82bn | 315.41m | 8.92bn | 5.97k | 28.83 | 2.56 | 17.65 | 4.91 | 1.41 | 1.41 | 8.12 | 15.90 | 0.3169 | 1.93 | 5.38 | 304,374.50 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |